FIELD: chemistry.
SUBSTANCE: invention relates to 4-(4-{[2-(4-chlorophenyl)-4,4-dimethylcyclohex-1-en-1-yl]methyl}piperazin-1-yl)-N-[(4-{[(trans-4-hydroxy-4-methylcyclohexyl)methyl]amino}-3-nitrophenyl)sulphonyl]-2-(1H-pyrrolo[2,3-b]pyridin-5-yloxy)benzamide and a pharmaceutical composition containing a therapeutically effective amount of said compound. As a result, 4-(4-{[2-(4-chlorophenyl)-4,4-dimethylcyclohex-1-en-1-yl]methyl}piperazin-1-yl)-N-[(4-{[(trans-4-hydroxy-4-methylcyclohexyl)methyl]amino}-3-nitrophenyl)sulphonyl]-2-(1H-pyrrolo[2,3-b]pyridin-5-yloxy)benzamide is obtained, which inhibits anti-apoptotic protein Blc2 activity.
EFFECT: high activity.
2 cl, 5 tbl, 378 ex
Title | Year | Author | Number |
---|---|---|---|
APOPTOSIS INDUCING AGENTS FOR TREATING MALIGNANT NEW GROWTH, AND IMMUNE AND AUTOIMMUNE DISEASES | 2010 |
|
RU2535347C2 |
APOPTOSIS-INDUCING MEANS FOR TREATMENT OF MALIGNANT TUMOUR AND IMMUNE AND AUTOIMMUNE DISEASES | 2015 |
|
RU2628885C2 |
APOPTOSIS-INDUCING MEDICATIONS FOR TREATING CANCER AND IMMUNE AND AUTOIMMUNE DISEASES | 2010 |
|
RU2554346C2 |
APOPTOSIS-INDUCING AGENTS FOR TREATMENT OF CANCER AND IMMUNE AND AUTOIMMUNE DISEASES | 2014 |
|
RU2662812C2 |
APOPTOSIS-INDUCING PREPARATIONS FOR TREATMENT OF CANCER AND IMMUNE AND AUTOIMMUNE DISEASES | 2009 |
|
RU2527450C2 |
APOPTOSIS INDUCING AGENTS SELECTIVE FOR Bcl-2 FOR CANCER AND IMMUNE DISEASES TREATMENT | 2013 |
|
RU2621052C2 |
BCL-2-SELECTIVE APOPTOSIS-INDUCING AGENTS FOR TREATING CANER AND IMMUNE DISEASES | 2010 |
|
RU2542994C2 |
APOPTOSIS-INDUCING AGENTS FOR TREATMENT OF CANCER AND IMMUNE AND AUTOIMMUNE DISEASES | 2010 |
|
RU2535203C2 |
SOLID DISPERSIONS CONTAINING AGENTS CAUSING APOPTOSIS | 2011 |
|
RU2598345C2 |
METHODS FOR TREATMENT USING SELECTIVE BCL-2 INHIBITORS | 2011 |
|
RU2593231C2 |
Authors
Dates
2016-01-27—Published
2010-05-26—Filed